SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maul Coin

Maul Coin is trending as the community actively coordinates to push the token's visibility on social platforms and trading sites, fueled by an active developer and hopes of reaching higher market caps. While enthusiasts celebrate its organic growth and community-driven approach, skeptics remain vocal about concerns regarding potential volatility, lack of a chart, and typical risks associated with low-cap crypto projects.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as community members rally around anticipation of a major upcoming partnership announcement, widely speculated to involve Ripple or XRP, alongside excitement over its new global stablecoin payroll integration with Stellar. While some investors focus on long-term utility and potential listings on major exchanges, community discourse remains polarized between optimistic holders eyeing generational wealth and skeptics dismissing recent price action as a pump-and-dump cycle.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its privacy-focused technology on the Base network, often citing support from Coinbase Ventures as a key catalyst. Enthusiasts are actively discussing the project's long-term potential for adoption and its mining and staking features, viewing it as a essential tool for digital sovereignty.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is capturing significant trader attention as a high-performance Layer 1 blockchain, with the community actively debating its potential to rival existing networks through speed and parallel processing. While price action has seen volatility alongside broader crypto market trends, discussions are heavily focused on long-term accumulation, staking rewards, and anticipation of upcoming ecosystem developments.

Monero

Monero (XMR) is trending as the community debates its role as the premier privacy-focused asset, with active discussions focusing on its unique resistance to regulatory oversight compared to transparent chains. Enthusiasts view it as a long-term store of value and a hedge against institutional tracking, while detractors continue to characterize the asset through speculative or cynical lenses.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is currently facing significant downward pressure and investor frustration, with the community actively debating whether the stock is a long-term 'holy grail' opportunity or a failing venture as it sits at a critical technical support level. Investors remain highly focused on upcoming manufacturing milestones and the potential for a short squeeze, while sentiment is polarized between those accumulating shares for a multi-year horizon and others disillusioned by the lack of immediate commercial catalysts.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is rallying around the project's longevity and humorous branding, actively promoting the token's presence across major platforms and cross-promoting with other popular assets. Enthusiasts are focused on organic growth and widespread adoption, frequently engaging with the community through social memes and dedicated poker events.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened volatility and intense social media discussion as the community debates its valuation and high price-to-earnings ratio ahead of its earnings release. While some investors remain cautious about margin pressures and the macro environment, others are highlighting strong unit-level economics, rapid store expansion, and high customer loyalty as reasons to hold the stock through the uncertainty.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Biocryst Pharmaceuticals is currently experiencing significant market movement and high volume driven by intense community speculation regarding a potential buyout or M&A activity. The stock has seen unusual after-hours trading and sustained call option accumulation, leading investors to closely monitor for official announcements or catalyst-driven price volatility.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter is experiencing significant social media engagement as the community actively rallies behind the long-standing UpDog token and various emerging Solana-based projects. Users are heavily discussing the utility of Jupiter's lending and borrowing protocols, while simultaneously promoting specific meme coins and liquidity strategies across the Solana ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MacroGenics (NASDAQ:MGNX) Share Price Crosses Above Fifty Day Moving Average   - Time to Sell?

MacroGenics (NASDAQ:MGNX) Shares Pass Above 50-Day Moving Average - Time to Sell...

MacroGenics (NASDAQ:MGNX) Upgraded to "Hold" at Wall Street Zen

Wall Street Zen raised MacroGenics from a "sell" rating to a "hold" rating in a report on Saturday...

<ul class="summary-bullets"><li>Barclays sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.</li><li>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028.&nbsp;</li><li>The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026.</li></ul> Barclays on Tuesday raised the firm's price target on MacroGenics on optimism regarding its pipeline of targeted cancer therapies.Barclays increased the price target on MacroGenics (MGNX) to $4 from $3 and kept an ‘Overweight’ rating on the shares following the company’s Q4 report on Monday. The firm sees the company's antibody-drug conjugate data in 2026 as a potential source of upside.<h2 class="st-heading-2">Pipeline Updates</h2>MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones in 2026, including initial clinical data from the early-stage studies of antibody drug conjugates MGC026 and MGC028, and from a study of its other experimental drug lorigerlimab.The company also seeks to submit an application seeking clearance to start clinical trials for its other ADC MGC030 in the third quarter of 2026, Risser said.Antibody-drug conjugates (ADCs) are targeted cancer therapies that deliver chemotherapy directly to cancer cells, minimizing damage to healthy tissue. Both Macrogenics’ MGC026 and MGC028 have demonstrated acceptable safety profiles to date as well as encouraging early evidence of anti-tumor activity. The company now anticipates reporting MGC026 clinical data in mid-2026, and MGC028 clinical data in the second half of 2026.Meanwhile, the U.S. Food and Drug Administration has placed a partial clinical hold on the company’s study evaluating lorigerlimab in patients with either platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). The company said that it is working closely with the agency to resolve the hold “as soon as possible” and anticipates a clinical update in mid-2026.The company ended the year with cash, cash equivalents and marketable securities of $189.9 million, which it expects to support its cash runway into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MGNX stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/MGNX">MGNX stock</a> has gained more than 50% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/viking-ceo-sees-its-obesity-drug-beating-novo-wegovy-in-weight-loss/cZdozzNRI7l">Viking CEO Sees Its Obesity Drug Beating Novo's Wegovy In Weight Loss</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MGNX Closes Up 45% On Wall Street Optimism For Experimental Cancer Therapies

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 

Equity

Barclays increased the price target on the stock to $4 from $3 and kept an ‘Overweight’ rating on the shares. 


Barclays Forecasts Strong Price Appreciation for MacroGenics (NASDAQ:MGNX) Stock

Barclays increased their price target on MacroGenics from $3.00 to $4.00 and gave the company an "overweight" rating in a research report on Tuesday...

MacroGenics (NASDAQ:MGNX) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

MacroGenics (NASDAQ:MGNX - Get Free Report) announced its earnings results on Monday. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of...

MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of +47.31% and +71.24%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BioLife Solutions, Inc. (BLFS) Surpasses Q4 Earnings and Revenue Estimates

BioLife Solutions (BLFS) delivered earnings and revenue surprises of +300.00% and +5.16%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts

MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) has been given a consensus rating of "Hold" by the seven ratings firms that are covering the firm, Marketbeat reports. One investment analyst has...

MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average - Should You Sell?

MacroGenics (NASDAQ:MGNX) Shares Pass Below 200 Day Moving Average - Here's What Happened...

MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts

Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received an average recommendation of "Hold" from the seven ratings firms that are covering the firm, MarketBeat reports. One equities...

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Macrogenics Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

MGNX
Macrogenics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MGNX News

MGNXMacrogenics Inc